Opinion|Videos|January 15, 2025
Analyzing Hepatotoxicity as a Safety Concern With PBC Therapies
Panelists discuss how hepatotoxicity risks vary among second-line primary biliary cholangitis (PBC) treatments, with seladelpar and elafibranor showing favorable hepatic safety profiles compared to obeticholic acid, though all require regular liver function monitoring and dose adjustments based on individual patient response and disease severity.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Hepatotoxicity is a key safety concern in PBC treatment. How do therapies like seladelpar, elafibranor, and obeticholic acid compare in terms of hepatotoxicity risk, and what monitoring strategies are recommended?
Advertisement
Related to this article
Experts highlighted recent gene therapy approvals for inherited immune disorders while addressing ongoing challenges in manufacturing, long-term safety, and patient access.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
At the 2026 ASTCT Gene Therapy Summit, experts highlighted how chronic pain, psychological challenges, and neurologic complications may persist despite successful treatment.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
ADA guidance ties monitoring choices to therapy, risk, and preference. Brooke Hudspeth, PharmD, explains how pharmacists help individualize the plan.
Twice-daily metronidazole dosing had outcomes comparable with those of thrice-daily dosing for confirmed anaerobic infections, minimizing drug exposure and cost while maintaining clinical efficacy.
Pharmacists navigate BCMA therapy sequencing in relapsed/refractory multiple myeloma, weighing linvoseltamab logistics, community readiness, safety monitoring, and smoother care transitions.
The provider-administered IL-23 inhibitor improved ACR20 response vs placebo after 2 doses in the phase 3 INSPIRE-1 and INSPIRE-2 trials.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Community Pharmacists Guide Patients New to Glucose Monitoring
2
CVS Health to Split Into 2 Public Companies, Separating Retail and Specialty Pharmacy
3
FDA Approves Tildrakizumab for Adults With Psoriatic Arthritis
4
Is Less More? Comparing Metronidazole Dosing in Confirmed Anaerobic Infections
5